GS
HRTX icon

Gagnon Securities’s Heron Therapeutics HRTX Stock Holding History

Gagnon Securities’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-617,703
Closed -$2.61M – 106
2022
Q3 		$2.61M Buy
617,703
+250,189
+68% +$979K 0.57% 37
2022
Q2 		$1.02M Buy
+367,514
New +$1.48M 0.21% 52

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Gagnon Securities's HRTX Position: Q4 2022 in Review

Gagnon Securities sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 617,703 shares — an estimated $2.61M sold.

Gagnon Securities first reported a position in HRTX in Q2 2022 and held it in 2 quarters. The position peaked at $2.61M in Q3 2022. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

  • Gagnon Securities reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Gagnon Securities sold 617,703 Heron Therapeutics shares in Q4 2022, an estimated $2.61M.
  • Gagnon Securities first reported a position in Heron Therapeutics in Q2 2022 and held it in 2 quarters.
  • Gagnon Securities's Heron Therapeutics position peaked at $2.61M in Q3 2022.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Gagnon Securities's 13F filing for Q4 2022, filed 7 Feb 2023.